Cargando…
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit fro...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858629/ https://www.ncbi.nlm.nih.gov/pubmed/31730012 http://dx.doi.org/10.1186/s40425-019-0805-8 |